Skip to content

Full-Thickness Macular Hole Surgery: A Comparison of Ten Techniques

Vitreoretinal Surgery for Full-Thickness Macular Hole: A Comparative Study of Ten Techniques

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07606404
Acronym
FTMH-10
Enrollment
120
Registered
2026-05-26
Start date
2026-05-25
Completion date
2028-05-27
Last updated
2026-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Macular Holes

Keywords

Full-Thickness Macular Hole, Pars Plana Vitrectomy, Internal Limiting Membrane Peeling, Inverted ILM Flap, ILM Flap, Optical Coherence Tomography, Macular Hole Closure, Best-Corrected Visual Acuity, Platelet-Rich Plasma, Amniotic Membrane Graft, Macular Hydrodissection, Surgical Technique

Brief summary

This study compares ten modern vitreoretinal surgical techniques for full-thickness macular hole repair. Participants will be randomly assigned to one of the surgical approaches during pars plana vitrectomy, using stratified randomization based on macular hole size to ensure balanced groups. The main goal is to determine which technique provides the highest anatomical closure rate on optical coherence tomography (OCT) and the best visual outcomes. Follow-up visits are scheduled at Day 7, Month 1, and Year 1 after surgery to assess OCT findings, visual acuity, safety outcomes, and the need for reoperation.

Detailed description

Full-thickness macular hole is a vision-threatening condition that is commonly treated with pars plana vitrectomy (PPV) and internal limiting membrane (ILM) peeling. While standard approaches achieve high closure rates in many cases, outcomes may vary depending on macular hole size and OCT morphology, and advanced surgical strategies (e.g., different ILM flap configurations, adjunctive biologic augmentation, hydrodissection, or grafting techniques) are increasingly used in clinical practice. This single-center, randomized, parallel-group interventional study will compare ten PPV-based surgical techniques for full-thickness macular hole repair. Eligible participants will include adults with full-thickness macular hole across a broad range of minimum linear diameter (MLD), including MLD \<250 µm. After eligibility confirmation and informed consent, participants will be randomized to one of the ten procedure groups. Randomization will be stratified by macular hole size into five predefined MLD strata to ensure balanced distribution of hole sizes across all intervention groups. Postoperative care and follow-up procedures will be standardized across groups according to the study protocol. Follow-up visits are scheduled at Day 7, Month 1, and Year 1 after surgery and will include clinical examinations and OCT imaging. The primary endpoint is anatomical macular hole closure on OCT at the prespecified primary time point. Secondary endpoints include best-corrected visual acuity (BCVA), OCT-based morphologic recovery parameters, intraoperative and postoperative complication rates, reoperation rates, and adverse event information through Year 1. The study aims to generate evidence to guide selection of surgical technique based on macular hole morphometric and clinical characteristics while maintaining patient safety.

Interventions

PROCEDUREPars Plana Vitrectomy (PPV)-Based Macular Hole Surgery

Pars plana vitrectomy (PPV) for full-thickness macular hole repair performed according to the randomized assigned technique (e.g., ERM peel, ILM peeling, ILM flap configurations, or macular edge hydrodissection), as specified in the protocol.

Autologous platelet-rich plasma (PRP) applied intraoperatively to the macular hole area as an adjunct to surgery, according to the study protocol.

OTHERHuman Amniotic Membrane (hAM) Graft

Human amniotic membrane (hAM) graft placed intraoperatively for macular hole repair, according to the study protocol.

Sponsors

Kazakh Eye Research Institute
Lead SponsorNETWORK

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Intervention model description

Parallel-group randomized trial comparing ten PPV-based surgical techniques for full-thickness macular hole repair, with stratified randomization by macular hole size into five predefined MLD strata.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Adults aged ≥18 years. Full-thickness macular hole (FTMH) eligible for pars plana vitrectomy (PPV). Symptom duration ≤12 months. Clear ocular media sufficient for high-quality OCT imaging. No prior pars plana vitrectomy in the study eye. No severe foveal atrophy on OCT. Able and willing to comply with postoperative positioning and follow-up visits. Written informed consent provided.

Exclusion criteria

A. Etiology-Related / Secondary Macular Holes: Traumatic macular hole. High myopia with posterior staphyloma (axial length \>28 mm and/or spherical equivalent ≤-8.0 D). Diabetic tractional retinal detachment (TRD) or significant tractional maculopathy. Retinal vascular occlusion-related macular hole. Uveitis-related macular hole. Advanced age-related macular degeneration (AMD) with foveal atrophy. B. Prior Interventions: Any prior pars plana vitrectomy in the study eye. C. Ocular Conditions That May Affect Outcomes or Safety: Active or recent ocular infection or inflammation (e.g., uveitis, endophthalmitis, keratitis). Uncontrolled glaucoma (intraocular pressure \>28 mmHg despite treatment). Media opacity precluding adequate OCT (e.g., dense cataract or corneal opacity). Geographic atrophy involving the fovea.

Design outcomes

Primary

MeasureTime frameDescription
Macular Hole Closure at 7 days7 dayProportion of participants with OCT-confirmed anatomical macular hole closure.
Macular Hole Closure at 1month1 monthProportion of participants with OCT-confirmed anatomical macular hole closure.
Macular Hole Closure at 1 Year1 yearProportion of participants with OCT-confirmed anatomical macular hole closure.

Secondary

MeasureTime frameDescription
BCVA at Day 77 daysBest-corrected visual acuity (BCVA) measured at Day 7 after surgery and recorded in logMAR units.
BCVA at 1 Month1 monthBest-corrected visual acuity (BCVA) measured at 1 month after surgery and recorded in logMAR units.
BCVA at 1 Year1 yearBest-corrected visual acuity (BCVA) measured at 1 year after surgery and recorded in logMAR units.

Countries

Kazakhstan

Contacts

CONTACTSanzhar Sambet, MD
sanzhrs@gmail.com+77758719834
CONTACTKairat Ruslanuly, MD
ruslanuly.kairat@gmail.com+77019008387
PRINCIPAL_INVESTIGATORSanzhar Sambet Sambet, MD

Kazakh Eye Research Institute

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 3, 2026